Akira Kurokawa - Santen Pharmaceutical CEO

SNPHY -- USA Stock  

USD 14.73  0.24  1.60%

  CEO
Mr. Akira Kurokawa was serving as Chairman of the Board, Chief Executive Officer and Representative Director in Santen Pharmaceutical Co., Ltd. since April 1, 2018. He joined the Company in April 1977. His previous titles include Director of Pharmaceutical Business, Executive Officer, Managing Executive Officer and Chief Operating Officer in the Company. He used to serve as President and Director in a subsidiary, Santen Holdings U.S. Inc.
Age: 65  CEO Since 2018      
81 6 6321 7000  http://www.santen.com

Management Efficiency

The company has return on total asset (ROA) of 6.91 % which means that it generated profit of $6.91 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 10.79 % meaning that it generated $10.79 on every $100 dollars invested by stockholders.

Similar Executives

Showing few of many executives

CEO Since

Elizabeth BarrettNovartis AG
2018
Osamu NagayamaRoche Holding AG
2006
Severin SchwanRoche Holding AG
2013
Michael HeuerRoche Holding AG
2018
Lamberto AndreottiBristol Myers Squibb Company
2015
Osamu NagayamaRoche Holding AG
2006
Olivier BrandicourtSanofi
2015
PerOlof AttingerRoche Holding AG
2010
William AndersonRoche Holding AG
2019
Olivier BrandicourtSanofi
2015
William AndersonRoche Holding AG
2019
Joseph JimenezNovartis AG
2010
Michael HeuerRoche Holding AG
2018
Bruno StriginiNovartis AG
2016
PerOlof AttingerRoche Holding AG
2010
Michael BallNovartis AG
2016
Severin SchwanRoche Holding AG
2013
Pascal SoriotAstraZeneca PLC
2012
Francesco BalestrieriNovartis AG
2019
Chris IlsleyNovartis AG
2018
Paul HudsonNovartis AG
2016

Entity Summary

Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 3805 people.Santen Pharmaceutical Co Ltd (SNPHY) is traded on OTC Market in USA and employs 3,805 people.

Santen Pharmaceutical Leadership Team

Satoshi Suzuki, Executive Officer, Chief Director of Planning
Kanoko Ohishi, Independent Director
Noriaki Yamamoto, CIO, Head of Information Systems Division and Corporate Officer
Akira Kurokawa, CEO and President Director, Member of Nominating Committee, Member of Executive Compensation Committee and Member of Corporate Strategy Committee
Hidetaka Mizutani, Manager of Finance & Accounting Group
Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR
Sadatoshi Furukado, Senior Managing Executive Officer, Director of Medical Business, Director
Ken Araki, Executive Officer, Senior Director of Global Business Development
Masamichi Sato, Head of CSR and General Affairs Division and Sr. Corporate Officer of Corporate Devel.
Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer
Akihiro Tsujimura, Executive Officer, Director of Asia Business
Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit
Frank Binder, Executive Officer, Chief Director of Supply Chain
Yutaro Shintaku, Independent Director
Akihiro Okumura, Independent Director
Yutaro Shinta, Independent Director
Jyrki Liljeroos, Executive Officer and Presidentident of Subsidiary
Shiro Hatagami, Manager of Finance & Accounting Group
Keizo Nakada, Executive Officer, Chief Director of Product Supply
Akio Kimura, Executive Officer, Chief Director of Reliability Guarantee
Naveed Shams, Chief Scientific Officer, Executive Officer and Presidentident and CEO of Subsidiary
Atsutoshi Ohta, Executive Officer, Chief Director of Production & Logistics
Hiroyuki Yamazaki, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Takahiro Morita, Executive Officer, Senior Director of Pharmaceutical Sales in Pharmaceutical Business Unit
Ye Liu, Executive Officer, General Manager of Subsidiary
Takayuki Katayama, Independent Director
Luis Iglesias, Executive Officer
Shigeo Taniuchi, Executive Officer and Presidentident of Subsidiary
Kunihito Minakawa, Independent Director

Stock Performance Indicators

Current Sentiment - SNPHY

Santen Pharmaceutical Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in Santen Pharmaceutical Co Ltd. What is your outlook on investing in Santen Pharmaceutical Co Ltd? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip
Currently Active Assets on Macroaxis
GOOG   
Purchased few shares of
few days ago
Traded for 1221.1
F   
Purchased over 300 shares of
few days ago
Traded for 9.33
VMW   
Purchased few shares of
few days ago
Traded for 192.14
GM   
Purchased over 70 shares of
few days ago
Traded for 39.57
MSFT   
Purchased over 20 shares of
few days ago
Traded for 121.05
Also please take a look at World Market Map. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Search macroaxis.com